Peptide Companion
Back to catalog
Peptide Companion
single
Other
Vial: 16 mg

Ara-290 (16 mg Vial)

Ara-290 (cibinetide) is an 11–amino acid non-erythropoietic peptide derived from erythropoietin’s helix-B domain. It selectively activates the innate repair receptor (IRR), an EPOR/CD131 heterodimer, to promote anti-inflammatory and tissue-protective effects without stimulating red blood cell production. Clinical trials have demonstrated benefits for diabetic neuropathy and sarcoidosis-related small-fiber neuropathy.

Detailed protocol below.

Dosing Schedule
WeekDaily DoseUnits (per injection) (mL)
Week 12 mg (2,000 mcg)25 units (0.25 mL)
Weeks 2–8 (or up to 16)4 mg (4,000 mcg)50 units (0.50 mL)
Supplies Needed
  • •Peptide Vials (Ara-290, 16 mg each):
  • •Insulin Syringes (U-100):
  • •Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
References

  • IUPHAR/BPS Guide to Pharmacology

    Cibinetide (ARA-290) ligand profile: structure, receptor binding, and pharmacology

    View source

  • Molecular Medicine (2014)

    Brines M. et al.: ARA 290 improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

    View source

  • Molecular Medicine (2013)

    Dahan A. et al.: ARA 290 improves symptoms in sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density

    View source

  • ClinicalTrials.gov (NCT02039687)

    Phase 2 study of ARA 290 on corneal nerve fiber density in sarcoidosis (1 mg vs 4 mg vs 8 mg daily SC for 28 days)

    View source

  • NCBI Bookshelf

    Stability and storage considerations for lyophilized peptide formulations

    View source

  • USP General Chapters

    Pharmaceutical compounding with bacteriostatic water: stability and beyond-use dating

    View source

  • Cleveland Clinic

    Subcutaneous injections: where and how to administer at home

    View source

  • Pain Reports (2017)

    Davis T. et al.: Targeting the innate repair receptor to treat neuropathy (review of ARA-290 mechanisms)

    View source

  • Investigative Ophthalmology & Visual Science (2016)

    Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber neuropathy

    View source

  • Peptides Journal (2016)

    Zhang W. et al.: ARA 290 relieves pathophysiological pain by targeting TRPV1 channel

    View source

  • Johns Hopkins Arthritis Center

    How to give a subcutaneous injection: patient guide

    View source

  • CDC

    Vaccine administration: subcutaneous route (angle, site, and technique guidance)

    View source

  • PMC Subcutaneous Drug Delivery Review

    Pharmacologic considerations of the subcutaneous injection route

    View source

Educational content adapted from peptidedosages.com. Not medical advice.